ECSP044973A - Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion - Google Patents

Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion

Info

Publication number
ECSP044973A
ECSP044973A EC2004004973A ECSP044973A ECSP044973A EC SP044973 A ECSP044973 A EC SP044973A EC 2004004973 A EC2004004973 A EC 2004004973A EC SP044973 A ECSP044973 A EC SP044973A EC SP044973 A ECSP044973 A EC SP044973A
Authority
EC
Ecuador
Prior art keywords
lercanidipine
chlorhydrate
preparation
polymorphic forms
new crystal
Prior art date
Application number
EC2004004973A
Other languages
English (en)
Inventor
Fausto Bonifacio
Francesco Campana
Iasi Gianluca De
Amedeo Leonardi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP044973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of ECSP044973A publication Critical patent/ECSP044973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La invención describe las nuevas formas crudas (A) y (B) de lercadinipina, las nuevas formas cristalinas (I) y (II) de clorhidrato de lercanidipina obtenidas a partir de las formas crudas, composiciones antihipertensivas, farmacéuticas que contienen como agente activo al menos una de las formas cristalinas (I) y (II) de clorhidrato de lercanidipina y métodos de uso de las mismas.
EC2004004973A 2001-08-06 2004-02-06 Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion ECSP044973A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001726A ITMI20011726A1 (it) 2001-08-06 2001-08-06 Forme polimorfe della lercanidipina cloridrato

Publications (1)

Publication Number Publication Date
ECSP044973A true ECSP044973A (es) 2004-06-28

Family

ID=11448245

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004004973A ECSP044973A (es) 2001-08-06 2004-02-06 Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion

Country Status (35)

Country Link
EP (4) EP1432683B9 (es)
JP (1) JP2005504045A (es)
KR (3) KR100626819B1 (es)
CN (2) CN100448847C (es)
AP (1) AP1766A (es)
AR (1) AR037139A1 (es)
AT (2) ATE453624T1 (es)
AU (1) AU2002327924C1 (es)
BR (1) BR0211739A (es)
CY (2) CY1109711T1 (es)
DE (2) DE60206787T2 (es)
DK (3) DK1600441T3 (es)
EA (1) EA005673B1 (es)
EC (1) ECSP044973A (es)
ES (3) ES2212759T3 (es)
HR (1) HRP20040156B1 (es)
HU (1) HU229563B1 (es)
IL (3) IL153917A (es)
IT (1) ITMI20011726A1 (es)
MA (1) MA27133A1 (es)
ME (2) MEP2908A (es)
MX (1) MXPA04001069A (es)
NO (2) NO325541B1 (es)
NZ (2) NZ531558A (es)
OA (1) OA12648A (es)
PE (1) PE20030328A1 (es)
PL (1) PL216066B1 (es)
PT (2) PT2157083E (es)
RS (1) RS52161B (es)
SI (3) SI1600441T1 (es)
TN (1) TNSN04024A1 (es)
UA (1) UA82988C2 (es)
UY (1) UY27410A1 (es)
WO (1) WO2003014084A1 (es)
ZA (1) ZA200401806B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
DE04801160T1 (de) * 2003-12-01 2007-08-09 Lifecycle Pharma A/S Pharmazeutische zusammensetzungen mit lercanidipin
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
EP1940790B1 (en) 2005-09-16 2015-09-02 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
KR100821165B1 (ko) * 2006-03-10 2008-04-14 동우신테크 주식회사 레르카니디핀 염산염의 제조 방법
US20110040097A1 (en) * 2006-12-29 2011-02-17 Dongwoo Syntech Co., Ltd Process for preparing lercanidipine hydrochloride
US20100104649A1 (en) * 2007-03-05 2010-04-29 Actavis Group Ptc Ehf Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate
SI2585051T2 (sl) 2010-06-23 2020-07-31 Krka, D.D., Novo Mesto Farmacevtske oralne odmerne oblike,ki obsegajo lerkanidipin in enalapril in njune farmacevtsko sprejemljive soli
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
EP2700632A4 (en) * 2011-04-18 2014-09-03 Hefei Beini Medical Technology Company Ltd METHOD FOR CLEANING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND PRODUCING NANOPARTICLES THEREFOR
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102584682A (zh) * 2011-12-31 2012-07-18 苏州二叶制药有限公司 盐酸乐卡地平的制备方法
CN103497075B (zh) * 2013-09-25 2016-03-23 山西北化关铝化工有限公司 水悬浮延期药造型粉
CN109232389B (zh) * 2018-05-15 2021-10-08 迪嘉药业集团有限公司 一种小粒度硝苯地平的结晶制备方法
CN115353485B (zh) * 2022-07-26 2024-04-19 山西双雁药业有限公司 从硝苯地平母液中回收硝苯地平的方法及应用
CN115671066B (zh) * 2022-11-21 2024-07-02 安徽宏业药业有限公司 一种盐酸乐卡地平片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596139A (en) * 1897-12-28 Process of generating acetylene gas
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
AP2002002620A0 (en) 2000-02-16 2002-09-30 Neurogen Corp Substituted arylpyrazines
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
AP2004002989A0 (en) 2004-03-31
ES2334678T3 (es) 2010-03-15
EP2157083A3 (en) 2010-03-24
EP1432683A1 (en) 2004-06-30
CN101475524B (zh) 2012-08-29
NO20040266L (no) 2004-03-24
KR100667687B1 (ko) 2007-01-12
HK1067123A1 (en) 2005-04-01
KR20050111799A (ko) 2005-11-28
ME01525B (me) 2011-02-10
SI1432683T1 (sl) 2006-04-30
EP2157083A2 (en) 2010-02-24
HUP0401163A3 (en) 2009-04-28
RS52161B (sr) 2012-08-31
PL216066B1 (pl) 2014-02-28
HUP0401163A2 (hu) 2004-09-28
EP2157083B1 (en) 2015-09-30
ATE307114T1 (de) 2005-11-15
MXPA04001069A (es) 2005-02-17
NO335651B1 (no) 2015-01-19
PT2157083E (pt) 2016-01-22
PL369522A1 (en) 2005-05-02
NZ541341A (en) 2007-02-23
HK1140487A1 (en) 2010-10-15
ATE453624T1 (de) 2010-01-15
ITMI20011726A1 (it) 2003-02-06
NO325541B1 (no) 2008-06-16
IL153917A (en) 2005-11-20
DK2157083T3 (en) 2015-11-02
EA200400280A1 (ru) 2004-08-26
KR100626819B1 (ko) 2006-09-20
DE60234961D1 (de) 2010-02-11
HRP20040156B1 (en) 2012-03-31
DK1600441T3 (da) 2010-02-08
WO2003014084A1 (en) 2003-02-20
ES2212759T1 (es) 2004-08-01
NO20082330L (no) 2004-03-24
IL164648A0 (en) 2005-12-18
AR037139A1 (es) 2004-10-27
OA12648A (en) 2006-06-16
EP1600441A3 (en) 2005-12-07
UY27410A1 (es) 2003-03-31
NZ531558A (en) 2005-12-23
CN1538957A (zh) 2004-10-20
CY1117051T1 (el) 2017-04-05
ITMI20011726A0 (it) 2001-08-06
HRP20040156A2 (en) 2004-08-31
MEP2908A (en) 2010-10-10
EP1432683B1 (en) 2005-10-19
DE60206787T2 (de) 2006-07-13
SI1600441T1 (sl) 2010-02-26
IL153917A0 (en) 2003-07-31
KR20040030903A (ko) 2004-04-09
ZA200401806B (en) 2005-06-29
MA27133A1 (fr) 2005-01-03
DK1432683T3 (da) 2006-03-06
CY1109711T1 (el) 2014-08-13
ES2555213T3 (es) 2015-12-29
KR20050043992A (ko) 2005-05-11
BR0211739A (pt) 2004-09-28
EP2036890A1 (en) 2009-03-18
ES2212759T3 (es) 2006-04-16
PE20030328A1 (es) 2003-05-09
EA005673B1 (ru) 2005-04-28
JP2005504045A (ja) 2005-02-10
PT1600441E (pt) 2010-01-20
SI2157083T1 (sl) 2016-01-29
EP1600441A2 (en) 2005-11-30
RS11304A (sr) 2007-02-05
UA82988C2 (uk) 2008-06-10
AU2002327924B2 (en) 2008-04-24
AP1766A (en) 2007-08-10
AU2002327924C1 (en) 2009-12-10
HU229563B1 (en) 2014-02-28
DE60206787D1 (de) 2006-03-02
CN100448847C (zh) 2009-01-07
CN101475524A (zh) 2009-07-08
IL164648A (en) 2007-02-11
HK1086263A1 (en) 2006-09-15
EP1600441B1 (en) 2009-12-30
TNSN04024A1 (en) 2006-06-01
EP1432683B9 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
ECSP044973A (es) Nuevas formas polimorficas cristalinas de clorhidrato de lercanidipina y proceso para su preparacion
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
JO2515B1 (en) Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
EE200300054A (et) Kinaasi inhibiitoritena toimivad bitsüklopürasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200200486A (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
DK1417206T3 (da) Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
NO20042805L (no) Nye forbindelser og deres anvendelse innen medisin, fremgangsmate for deres fremstilling og farmaoytiske sammensetninger som inneholder dem
NO20013254L (no) Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem
DE602006001411D1 (de) Kristallinform gamma-d von Ivabradine-hydrochlorid, Verfahren zu dessen Herstellung und diesen enthaltende Pharmazeutische Zusammensetzung
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
EA200401515A1 (ru) Новые фармацевтические композиции, содержащие флибансерин в полиморфной модификации а
NO20023643D0 (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
UY29320A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, así como preparaciones farmacéuticas que las contienen
ECSP066517A (es) Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
BRPI0012475B1 (pt) composto derivado de titánio, seu processo de preparação e utilização, bem como composição para uso oral compreendendo o mesmo.
CL2004000872A1 (es) Compuestos derivados de m-l-d, donde m es la porcion aglicona de un macrolido, l es un grupo de enlace y d es una subunidad antiinflamatoria no esteroidal o una subunidad antiinflamatoria esteroidal; composicion farmaceutica, y uso para el tratamient
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина